Supplementary Materials

The PDF file includes:

  • Fig. S1. PD-1H KO mice do not develop lupus nephritis.
  • Fig. S2. Serum cytokines from WT and PD-1H KO mice.
  • Fig. S3. PD-1H modulates type I IFNs, and type I IFN response genes are modestly up-regulated in cutaneous lupus lesions of PD-1H KO mice.
  • Fig. S4. Quantification of mass cytometry from WT and PD-1H KO skin.
  • Fig. S5. PD-1H KO mice and WT mice develop similar pristane-induced kidney disease.
  • Fig. S6. IHC of human control skin, discoid lupus, and LP.
  • Fig. S7. Multiplex immunofluorescence of human DLE and control skin.
  • Fig. S8. Histology and immunophenotyping of MRL/lpr mice treated with a PD-1H agonist.
  • Fig. S9. Proteinuria, kidney inflammation, and lupus nephritis in MRL/lpr mice treated with a PD-1H agonist.
  • Fig. S10. The PD-1H agonist MH5A does not affect T cell signaling or pDC and neutrophil function from PD-1H KO mice.
  • Legends for tables S1 and S2
  • Legend for data file S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Histological scoring of cutaneous lupus lesions.
  • Table S2 (Microsoft Excel format). Murine mass cytometry antibody panel.
  • Data file S1 (Microsoft Excel format). Primary data.